Barcelona, Spain, April 20, 2022 – Inke, a leading global manufacturer of inhalation APIs wholly owned by Neuraxpharm Group, announces it is investing €9 million to increase production capacity for inhalation APIs. The investment will allow Inke to triple the production capacity of chemical synthesis and the micronisation of inhalation APIs at its manufacturing plant in Castellbisbal, Barcelona, by 2024. The company expects that approximately 80% of this €9 million investment will be deployed by the end of this year. The expansion of Inke’s multipurpose plant allows the company to meet the increasing global demand for inhalation APIs: Urbanisation, especially in
The post Leading inhalation APIs expert Inke to triple production capacity appeared first on Pharma Mirror Magazine.
